Medical oncologist Douglas Yee, MD, a nationally recognized breast cancer researcher and chair of the ASCO 2012 - 2013 Scientific Program Committee, presents and discusses the various elements of this year's ASCO program.
Yee's laboratory research on the growth regulation of tumors provided the foundation for the development of new anti-cancer drugs…Continue
Added by Editorial Team on May 31, 2013 at 12:30pm — No Comments
“Fifty years of modern oncology has delivered dramatic progress, offering our patients better treatments, more cures and a better quality of life during and after therapy," said Bruce J. Roth, MD, Chair of the ASCO’s Cancer Communications Committee. “Studies being presented at this year’s Annual Meeting of the American Society of Clinical Oncology embody a new era of precision medicine, in which we’re taking better aim at vital targets on cancer and immune cells. Several studies also…Continue
Added by Editorial Team on May 31, 2013 at 9:00am — No Comments
In this program, Antoinette R. Tan, MD, a medical oncologists at the The Cancer Institute of New Jersey, discusses the various aspects of the scientific educational value and aspects of the 2013 Annual Meeting of the American Society of Clinical Oncology, being held from May 31 to June 4, 2013 in Chicago, Ill.
Added by Editorial Team on May 31, 2013 at 12:00am — No Comments
A Phase II clinical trial in patients with metastatic melanoma using intravenous administration of a nonattenuated reovirus type-3 Dearing (RT3D; Reolysin(®, Oncolytics Biotech Inc) in combination with carboplatin and paclitaxel (NCT00984464) met primary endpoint for the first stage of the trial. Reolysin is…Continue
Added by Editorial Team on May 22, 2013 at 6:30pm — No Comments
The design of intravenous needleless connectors or NCs plays a substantial role in development of the potentially deadly hospital acquired-catheter related blood stream infection (HA-CRBSI) and the associated risk. Research on different types of needleless IV connectors led a Johns Hopkins cancer center to pilot a new "neutral pressure" IV connector. The results were presented at the at the 38th Annual Congress of the Oncology Nursing Society held April 25-28, 2013 in Washington, D.C.…Continue
Added by Editorial Team on May 21, 2013 at 4:00pm — No Comments
Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin (CMC-544) in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for intensive high-dose chemotherapy.
In this study, inotuzumab ozogamicin was administered on a once-a-month schedule in combination with rituximab…Continue
Added by Editorial Team on May 20, 2013 at 6:00pm — No Comments
Earlier today, Bayer HealthCare announced that the company has started enrolling patients in an international Phase III trial to evaluate the efficacy and safety of regorafenib (Stivarga®) for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib (Nexavar®, Bayer/Onyx) treatment. Regorafenib is an oral multi-kinase inhibitor that inhibits…Continue
Added by Editorial Team on May 15, 2013 at 9:30pm — No Comments
The U.S. Food and Drug Administration (FDA) has approved erlotinib tablets (Tarceva®; Genentech, Astellas Pharma), a once-daily, oral non-chemotherapy medicine for the initial or first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have certain epidermal growth factor receptor (EGFR) activating mutations as detected by an FDA-approved test. In…Continue
Added by Editorial Team on May 14, 2013 at 8:30pm — No Comments
In an op-ed article titled "My Medical Choice" published earlier today in the New York Times, famed Hollywood actress Angelina Jolie writes that she, after learning that she carries a mutation of the BRCA1 gene which critically increases her risk of developing breast and ovarian cancer, made the decision to have a preventive or prophylactic double…Continue
Phase III clinical trial results from PRELUDE study, which explored the enzastaurin (Eli Lilly and Company; Lilly Oncology) as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL), failed to show a statistically significant increase compared to placebo…Continue
Added by Peter Hofland, PhD on May 10, 2013 at 6:00am — No Comments
A new multi-center trial of high dose Interleukin-2 (HD rIL-2; Aldesleukin for Injection/Proleukin®; Prometheus Laboratories Inc, San Diego, CA/Novartis Vaccines and Diagnostics, Emeryville, CA) plus vemurafenib (Zelboraf®, Genentech/Roche) therapy in patients with BRAF V600 mutation-positive…Continue
Added by Peter Hofland, PhD on May 9, 2013 at 10:00am — No Comments
Data presented today at the 2013 Annual Meeting for the American Urological Association by Johns Hopkins University School of Medicine researchers demonstrated that Decipher™ (GenomeDx Biosciences), a transformative genomic test that provides a readout of the risk of metastatic disease and disease progression for individual men with prostate cancer, predicted the onset of rapid metastatic disease (RMD) in patients following…Continue
Added by Editorial Team on May 8, 2013 at 9:00pm — No Comments
Data from various cancer registries in the United Kingdom shows that Bladder Cancer is a common cancer among men and women in the United Kingdom, with 10.335 new cases diagnosed in 2008.  It is one of the most frequently diagnosed cancer of the urinary system and accounts for 1 in every 30 new cases. With 7,390 new cases diagnosed in 2008, is a the 4th most common cancer in men  and 11th in women (2,945 female cases), giving a male: female ration of…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 9:30pm — No Comments
Date presented at the 2013 Conference of The American Society of Breast Surgeons (ASBrS) shows promising results for non-surgical cryoablation treatment of breast cancer. The results were presented by Eisuke Fukuma, M.D., Ph.D., Chairman and Director of Breast Center, Director of Breast Disease Kameda Medical Center in Kamogawa City, Chiba, Japan.
Cryoablation, also be called percutaneous ablation,…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 5:30pm — No Comments
Results of the ASPECCT ('763) trial, a phase III head-to-head study evaluating panitumumab (Vectibix®; Amgen Inc.) versus cetuximab (Erbitux®; ImClone LLC/Eli Lilly and Company and Bristol-Myers Squibb Company) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 3:00pm — No Comments
Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman’s breast cancer risk. A study discussing data that suggests that exercise influences estrogen metabolism was published earlier today in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Exercise boosts the immune system and helps keep a persons weight in…Continue
Added by Editorial Team on May 7, 2013 at 1:00pm — No Comments
Men who reported sleep disorders or ongoing sleeping problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Sleep can often be a barometer of your overall health for both men and women. In many cases, people in good health…Continue
Added by Editorial Team on May 7, 2013 at 12:30pm — No Comments
Added by Editorial Team on May 5, 2013 at 9:00pm — No Comments
An article supported by nearly 120 leukemia specialists published today in Blood, the most cited peer-reviewed publication in the field of hematology published by the American Society of Hematology, increases in costs of treatments for chronic myeloid leukemia…Continue
Added by Editorial Team on May 5, 2013 at 3:00pm — No Comments